These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 1756029)

  • 1. Calcium--a neglected key factor in arteriosclerosis. The pathogenic role of arterial calcium overload and its prevention by calcium antagonists.
    Fleckenstein-Grün G; Fleckenstein A
    Ann Med; 1991; 23(5):589-99. PubMed ID: 1756029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of calcium in arteriosclerosis--experimental evaluation of antiarteriosclerotic potencies of Ca antagonists. Study Group for Calcium Antagonism.
    Fleckenstein-Grün G; Thimm F; Frey M; Czirfusz A
    Basic Res Cardiol; 1994; 89 Suppl 1():145-59. PubMed ID: 7945169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of calcium antagonists in progression of arteriosclerosis. Evidence from animal experiments and clinical experience. Part I. Preventive effects of calcium antagonists in animal experiments.
    Frey M; Just H
    Basic Res Cardiol; 1994; 89 Suppl 1():161-76. PubMed ID: 7945170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differentiation between calcium- and cholesterol-dominated types of arteriosclerotic lesions: antiarteriosclerotic aspects of calcium antagonists.
    Fleckenstein-Grün G; Frey M; Thimm F; Luley C; Czirfusz A; Fleckenstein A
    J Cardiovasc Pharmacol; 1991; 18 Suppl 6():S1-9. PubMed ID: 1725909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experimental vasoprotection by calcium antagonists against calcium-mediated arteriosclerotic alterations.
    Fleckenstein-Grün G; Thimm F; Czirfuzs A; Matyas S; Frey M
    J Cardiovasc Pharmacol; 1994; 24 Suppl 2():S75-84. PubMed ID: 7898099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcium overload--an important cellular mechanism in hypertension and arteriosclerosis.
    Fleckenstein-Grün G; Frey M; Thimm F; Hofgärtner W; Fleckenstein A
    Drugs; 1992; 44 Suppl 1():23-30. PubMed ID: 1283581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective effects of various calcium antagonists against experimental arteriosclerosis.
    Fleckenstein-Grün G; Frey M; Thimm F; Fleckenstein A
    J Hum Hypertens; 1992 Dec; 6 Suppl 1():S13-8. PubMed ID: 1293304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Excessive mural calcium overload--a predominant causal factor in the development of stenosing coronary plaques in humans.
    Fleckenstein A; Frey M; Thimm F; Fleckenstein-Grün G
    Cardiovasc Drugs Ther; 1990 Aug; 4 Suppl 5():1005-13. PubMed ID: 2076386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Possibilities in the future application of calcium antagonists. Is the prevention of blood vessel calcinosis possible?].
    Fleckenstein A; Frey M; Fleckenstein-Grün G
    Fortschr Med; 1984 Jul; 102(27-28):713-7. PubMed ID: 6479813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression and regression by verapamil of vitamin D3-induced calcific medial degeneration in coronary arteries of rats.
    Fleckenstein-Grün G; Thimm F; Frey M; Matyas S
    J Cardiovasc Pharmacol; 1995 Aug; 26(2):207-13. PubMed ID: 7475044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experimental basis of the long-term therapy of arterial hypertension with calcium antagonists.
    Fleckenstein A; Frey M; Zorn J; Fleckenstein-Grün G
    Am J Cardiol; 1985 Dec; 56(16):3H-14H. PubMed ID: 2416214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antihypertensive and arterial anticalcinotic effects of calcium antagonists.
    Fleckenstein A; Frey M; Fleckenstein-Grün G
    Am J Cardiol; 1986 Feb; 57(7):1D-10D. PubMed ID: 3513510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Misinterpretation of coronary cholesterol atheromata in cholesterol-fed rabbits as suitable model for conventional human coronary plaques.
    Thimm F; Frey M; Fleckenstein-Grün G
    Adv Exp Med Biol; 1994; 361():417-24. PubMed ID: 7597965
    [No Abstract]   [Full Text] [Related]  

  • 14. Antiatherogenic properties of calcium antagonists.
    Weinstein DB; Heider JG
    Am J Cardiol; 1987 Jan; 59(3):163B-172B. PubMed ID: 2433931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Model experiments on anticalcinotic and antiarteriosclerotic arterial protection with calcium antagonists.
    Fleckenstein A
    J Mol Cell Cardiol; 1987 May; 19 Suppl 2():109-21. PubMed ID: 3305965
    [No Abstract]   [Full Text] [Related]  

  • 16. Anti-atherosclerotic effects of calcium antagonists.
    Holzgreve H; Bürkle B
    J Hypertens Suppl; 1993 Mar; 11(1):S55-9. PubMed ID: 8483024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of action of calcium antagonists in heart and vascular smooth muscle.
    Fleckenstein A; Fleckenstein-Grün G
    Eur Heart J; 1988 Jun; 9 Suppl H():95-9. PubMed ID: 3049099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of calcium antagonists in the treatment of atherosclerosis and hypertension.
    Ouchi Y; Orimo H
    J Cardiovasc Pharmacol; 1990; 16 Suppl 2():S1-4. PubMed ID: 1369701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Atheroma and calcium antagonists].
    Lechat P; Hadjiisky P
    Therapie; 1993; 48 Spec No():665-70. PubMed ID: 8091352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The antiatherogenic effects of calcium antagonists.
    Keogh AM; Schroeder JS
    Am J Hypertens; 1991 Jul; 4(7 Pt 2):512S-518S. PubMed ID: 1654938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.